Citations

Mayo Clinic

Clear

88156 citation(s) found for "NA".

Key Performance Indicators for Clinical Pharmacy Practice and Administration in Inpatient/Acute Care Settings: An Opinion of the Clinical Administration Practice and Research Network of the American College of Clinical Pharmacy
Mercado, Angela , Noble, Jacob M. , Irwin, Adriane N. , Badowski, Melissa E. , Bangalore, Nitish , Caliendo, G C, Chan, David C. M. , Dumont, Zachary J. , Groth, Christine M. , Humaideh, Mais Anis, Nguyen, TuTran , Salvatus, Marc , Sullivan, Jesse , Thambi, Mathew , Welch, R , Noble, Jacob , Sullivan, Jesse B , Welch, Ron W , Parrish, Richard H , Dumont, Zack , Caliendo, Gina, Thambi, Mathew , Parrish, Richard H.

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | July 11, 2026 | Volume: 9 | Issue: 8 | Pages: No page available

10.1002/jac5.70252 | PMID 42432869 Get It

ABSTRACT Key performance indicators (KPIs) are quantifiable measures that describe critical success factors of an organization. Their vital role in ensuring the delivery of quality health care services necessitates the development of KPIs relevant to inpatient clinical pharmacy practice. This opinion paper from the American College of Clinical Pharmacy (ACCP) Clinical Administration Practice and Research Network (CADM PRN) describes the rationale, methodology, and outcomes of a consensus process to identify a focused set of inpatient/acute care clinical pharmacy KPIs. Leveraging a modified Delphi approach, the CADM PRN convened an Expert Panel of clinical pharmacy leader members to build a consensus‐driven set of KPIs reflecting clinical, operational, patient‐centered, and financial contributions of clinical pharmacists in the inpatient/acute care setting. From a previous ACCP White Paper, a total of 15 KPIs were identified across four domains: (1) clinical practice and patient safety, (2) clinical outcomes and readmissions, (3) medication education and patient engagement, and (4) financial and operational value. The CADM PRN posits that the establishment and implementation of standardized KPIs are essential for measuring and demonstrating the value of clinical pharmacy services in modern health care, offers pragmatic, consensus‐based KPIs for evaluating clinical pharmacy services supporting resource justification, and advancing the visibility and impact of pharmacists in acute care practice. As hospitals shift toward value‐based care, robust KPI frameworks will be critical for optimizing patient outcomes, supporting financial sustainability, and justifying appropriate staffing. Future efforts should focus on pilot testing, addressing implementation barriers, and achieving broader acceptance for KPIs across the profession.
Longitudinal Analysis of Heparin-Binding Protein (HBP) and Serum Amyloid a Protein (SAA) Versus Interleukin 6 (IL-6), C-Reactive Protein (CRP), and Procalcitonin (PCT) During Both the Acute Postoperative Period and Recovery at Three Months From Non-emergen
Laudański, Krzysztof , Ahmed, Ahmed Sayed, Mahmoud, Mohamed A., Gad, Hossam , Harris, Benjamin R.E., Smith, Ryan, Zhu, Dandan, Elgazar, Abdelhamed , Vasishta, Anil, Ognjen, Gajic, Diedrich, Daniel A. , Crestanello, Juan, Smith, Ryan J. , Gad, Hossam , Mahmoud, Mohamed A. , Harris, Benjamin R.E.

Clinical Medicine Insights: Cardiology | July 11, 2026 | Volume: 20 | Issue: No issue available | Pages: No page available

10.1177/11795468261462607 | PMID 42436667 Get It

Variability in novel inflammatory markers (HBP and SAA) post-surgery could indicate ongoing perioperative inflammation. This pilot cohort study collected blood from 99 patients undergoing elective cardiac surgery at baseline, 24 hours, 7 days, and 3 months post-surgery. Inflammatory markers (HBP, SAA, PCT, CRP, IL-6) were measured with a point-of-care device. Demographic and clinical data were extracted from health records. Serum SAA increased significantly in the acute postoperative phase (M e [IQR];SAA baseline =81.1[87] vs SAA 24hr= 232.65[88.02];U[72]=2343,p<0.0001), remained elevated at 7 days (Me 7d =252.6[88.56];U[57]=1484,p<0.0001) and were still more pronounced than baseline at t 3m (Me 3m =118.44[101.52];U[38]=448,p=0.0008). HBP showed a significant rise at seven days (HBP baseline =45[26;89] vs HBP 7d =121[69.75;224.5]; U[56]=805,p<0.0001) then returned to near baseline by t 3m (Me 3m =32.5[15.75;98.5]). Traditional inflammatory markers PCT, CRP, and IL-6 demonstrated a rapid increase at t 24h and plateaued at t 7d . None of the biomarkers showed variability at baseline or postoperatively with preoperative status or postoperative complications. Cluster analysis of the inflammatory markers at 24 hours (t 24h ) identified distinct subgroups. Cluster #1-patients with a modest increase in all markers; Cluster#2 characterized with a robust increase in IL-6; Cluster #3 showed increase in CRP and decline in HBP; Cluster #4 showed a modest increase in IL-6 and decline in HBP; Cluster #5 represented a decline in both CRP and SAA. Patients in these clusters differ with respect to age, pre-existing peripheral artery disease, and borderline differences in perioperative acetaminophen use. SAA and HBP remain elevated longer than IL-6, CRP, and PCT after surgery, suggesting that inflammation may persist beyond 3 months.
Efficacy and Safety of Pharmaceutically Manufactured Cannabidiol in Recurrent Pericarditis: A Phase II Clinical Trial
Klein, Allan L. , Cremer, Paul , Abbate, Antonio , Salik, Jonathan R. , Thomas, Georgia , Haider, Syed Waqas , Hagerty, Tracy E., Lin, David, Waggoner, Thomas, Narine, Kelly A.D., Parker, Andrea B., Hamer, Andrew, Luis, Sushil A , Klein, Allan , Cremer, Paul C , Abbate, Antonio , Salik, Jonathan R , Thomas, Georgia K , Haider, Syed Waqas , Waggoner, Thomas E , Nicholls, Stephen J , Narine, Kelly A D , Luis, Sushil Allen , Hagerty, Tracy , Nicholls, Stephen J. , Kirwan, Bridget‐Anne

Journal of the American Heart Association | July 11, 2026 | Volume: 15 | Issue: 14 | Pages: No page available

10.1161/jaha.125.047605 | PMID 42432451 Get It

Background Recurrent pericarditis may be mediated through inappropriate activation of the NACHT, leucine‐rich repeat, and pyrin domain‐containing protein 3 inflammasome. Pharmaceutically manufactured cannabidiol is an oral formulation that inhibits NACHT, leucine‐rich repeat, and pyrin domain‐containing protein 3 inflammasome activation and development of pericarditis in a preclinical model. Methods This Phase 2, open‐label, multicenter trial included adult patients with symptomatic recurrent pericarditis: pericarditis chest pain ≥4 on an 11‐point numerical rating scale with an elevated C‐reactive protein (≥1 mg/dL) or at least mild pericardial inflammation on cardiac magnetic resonance imaging. At enrollment, patients were on stable doses of non‐steroidal anti‐inflammatory drugs, colchicine, and/or corticosteroids. Cannabidiol was administered during an 8‐week treatment period and an optional 18‐week extension period when background therapy was tapered and discontinued. The primary efficacy end point was change in patient‐reported pericarditis pain. Secondary end points included normalization of C‐reactive protein and percentage of patients with recurrences. Results Among 27 patients (18 women, mean age 53 years), baseline maximal numerical rating scale pain score was 5.8±1.7, and 10 patients had elevated C‐reactive protein. At Week 8, maximal numerical rating scale pain score was 2.1±1.8, and median time to numerical rating scale score ≤2 was 5 days. Among the 10 patients with baseline C‐reactive protein elevation, C‐reactive protein was normal at Week 8 in 8 patients (80%). During the extension period, 17 (71%) of 24 patients remained free of pericarditis recurrence. A serious adverse event leading to cannabidiol discontinuation occurred in 1 patient. Conclusions In symptomatic patients with recurrent pericarditis, pharmaceutically manufactured cannabidiol appears safe and associated with reductions in pericarditis pain and systemic inflammation. Registration URL: clinicaltrials.gov ; Unique Identifier: NCT05494788.
Targeting the Cardiometabolic Axis: An Integrative Review on Therapeutic Advances
Duru, Paul, Tasouli-Drakou, Vasiliki , Ramazani, Noyan , Hartnett, Sigurd, Cyrus, Tillmann, Tak, Tahir

International Journal of Angiology | July 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/a-2904-8884 Get It

Abstract Obesity has emerged as one of the most significant health challenges, with prevalence rates exceeding 30% in many regions and contributing substantially to the burden of cardiovascular disease (CVD). This review synthesized findings from clinical trials, systematic reviews, and narrative reviews. Key outcomes assessed included heart failure symptoms, echocardiographic parameters, incidence of atrial fibrillation (AF), inflammation biomarkers, and overall cardiovascular morbidity and mortality. Across studies, obesity was consistently linked with elevated risk of coronary heart disease, AF, stroke, and heart failure with preserved ejection fraction (HFpEF). Central adiposity and ectopic fat depots, especially epicardial fat, emerged as critical mediators of CVD progression. Semaglutide, tirzepatide, and other agents have demonstrated robust effects in reducing weight, improving functional capacity, and attenuating cardiac remodeling, with additional benefits in lowering inflammation markers and natriuretic peptides independent of weight loss. Notably, patients with AF and obesity-related HFpEF appeared to experience greater symptomatic and functional improvements with semaglutide compared with those without AF. Conversely, evidence on the obesity paradox and metabolically healthy obesity revealed heterogeneity, with some subgroups demonstrating preserved or even improved survival despite excess adiposity, though these effects may be confounded by differences in cardiorespiratory fitness and lead time biases. Obesity remains a powerful risk factor for CVD, mediated through both metabolic and structural pathways. The advent of anti-obesity pharmacotherapies represents a watershed moment for cardiology, offering disease-modifying potential in obesity-related heart failure and beyond. Future research should refine the understanding of obesity phenotypes, and the role of fat distribution and cardiorespiratory fitness.
Comparative Efficacy of Topical Anesthetic Compounds Prior to 1927-nm Fractional Thulium Fiber Laser
Kang, Bianca Y. , Harvey, Jamison A., Mead‐Harvey, Carolyn , Hoss, Elika

Dermatologic Surgery | July 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/dss.0000000000005257 | PMID 42430730 Get It

Real-World Practice in Secondary Stroke Prevention Following Embolic Stroke of Undetermined Source
Nour, Hassan Aboul , Siegler, James E. , Thompson, Sean, Glover, Patrick , Daniel, J, Penckofer, Mary , Smith, M A, Yaghi, Shadi , Chen, L, Kerrigan, Deborah , Kirchhoffer, Kaitlyn, Kam, Wayneho , Melkumova, Emiliya , Lineback, Christina , Thottempudi, Neeharika , Heaton, Sharon, Linares, Guillermo , Singh, Eesha , Fernández, Camilo José Albert, Dumitrașcu, Oana , Bowman, Anna, Porto, Camelia Valhuerdi, Chahien, Dalia, Herpich, Franziska , Kang, Jieun , Nelson, Ashley , Shahrivari, Mahan, Khezri, Nicole, Lewis, Skylar, Sathya, Anvitha , Leung, Lester Y. , Eklund, Kelsey , Rojas-Soto, Diana , Nedelcu, Simona , Kasab, Sami Al , Coevering, Russell J. Van, Thon, Jesse , Aboul-Nour, Hassan , Siegler, James E , Thompson, Sean L , Glover, Patrick , Daniel, Jean-Philippe Auguste , Smith, Matthew M , Ro, Jennifer , Chen, Lucia , D'Souza, Marissa , Khasiyev, Farid , Kerrigan, Deborah , Sharma, Richa , Aziz, Yasmin , Kirchhoffer, Kaitlyn , Kam, Wayneho , Melkumova, Emiliya , Sloane, Kelly L , Lineback, Christina M , Thottempudi, Neeharika , Heaton, Sharon , Linares, Guillermo , Almallouhi, Eyad , Stretz, Christoph , Dumitrascu, Oana M , Culbertson, Collin J , Elangovan, Cheran , Bowman, Anna , Valhuerdi Porto, Camelia , Chahien, Dalia , Herpich, Franziska , Farooqui, Mudassir , Kang, Jieun , de Havenon, Adam H , Nelson, Ashley , Shahrivari, Mahan , Stamm, Brian , Khezri, Nicole , Lewis, Skylar , Sathya, Anvitha , Leung, Lester Y , Eklund, Kelsey , Rojas-Soto, Diana , Nedelcu, Simona , Al Kasab, Sami , Thon, Jesse , Jillella, Dinesh V , Nahab, Fadi B , Yaghi, Shadi , Penckofer, Mary , D’Souza, Marissa , Khasiyev, Farid , Sharma, Richa , Aziz, Yasmin , Almallouhi, Eyad , Stretz, Christoph , Elangovan, Cheran , Havenon, Adam de , Stamm, Brian , Coevering, Russell J. Van , Jillella, Dinesh

Neurology Clinical Practice | July 10, 2026 | Volume: 16 | Issue: 4 | Pages: No page available

10.1212/cpj.0000000000200631 | PMID 42430672 Get It

Reply to: “Beyond Response Rates: Interpreting Long-Term Benefit in CheckMate 743” and “Beyond Statistical Significance: Methodological Fragility and Censoring Bias in the 5-Year Update of CheckMate 743”
Scherpereel, Arnaud , Mansfield, Aaron S. , Grossi, Francesco , Popat, Sanjay , Baas, Paul , Nowak, Anna K. , Tsao, Anne S. , Fujimoto, Nobukazu , Aragón, Yolanda Bautista, Talbot, Toby, Kaplan, Muhammet A., Soomro, Raheela, Hu, Nan , Ip, Virginia , Peters, Solange , Talbot, Toby , Kowalski, Dariusz , Cardona, Andrés F , Lee, Adam , Hung, Yu-Han , Zalcman, Gérard , Mansfield, Aaron S , Nowak, Anna K , Popat, Sanjay , Baas, Paul , Grossi, Francesco , Tsao, Anne S. , Peters, Solange , Bautista-Aragón, Yolanda, Kowalski, Dariusz M. , Cardona, Andrés F. , Zalcman, Gérard

Journal of Clinical Oncology | July 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1200/jco-26-01153 | PMID 42430671 Get It

Long-Term Outcomes and Surgical Conversion After Immunotherapy in Microsatellite Instability-H Biliary Tract Cancers
Shah, Priyanshi , Peersen, Anina, Sahai, Vaibhav , Mahipal, Amit , Naleid, Nikolas , Borad, Mitesh J. , Bekaii‐Saab, Tanios , Sonbol, Mohamad Bassam , Majeed, Umair , Babiker, Hani M. , O’Donnell, Conor, Malla, Midhun , Conboy, Caitlin B. , Fonkoua, Lionel Kankeu, Washburn, L. , Peterson, Nicole , Carr, Ryan M., Starlinger, P, Smoot, Rory, Warner, Susanne, Ilyas, Sumera L., Heimbach, Julie, Borad, Mitesh J , O'Donnell, Conor D J , Conboy, Caitlin B , Washburn, Leslie A , Halfdanarson, Thorvardur R , Peterson, Nicole , McWilliams, Robert R , Graham, Rondell P , Gores, Gregory J. , Roberts, Lewis R , Ou, Fang-Shu , Tran, Nguyen , Mahipal, Amit , Sonbol, Mohamad B , Bekaii-Saab, Tanios S , Babiker, Hani , Majeed, Umair , Sahai, Vaibhav , Peersen, Anina, Gupta, Garima , Fonkoua, Lionel Aurelien Kankeu , Hálfdánarson, Þorvarður R. , McWilliams, Robert R. , Carr, Ryan M , Graham, Rondell P. , Starlinger, Patrick, Warner, Susanne, Ilyas, Sumera I. , Gores, Gregory J. , Roberts, Lewis R. , Heimbach, Julie K. , Ou, Fang‐Shu , Tran, Nguyen H.

JCO Precision Oncology | July 10, 2026 | Volume: 10 | Issue: 7 | Pages: No page available

10.1200/po-25-01156 | PMID 42430699 Get It

PURPOSE Deficient mismatch repair/microsatellite instability (dMMR, MSI-H) in biliary tract cancers (BTCs) is observed in 1%-5% of tumors. MSI-H across solid tumors has demonstrated durable response to immune checkpoint inhibitors (ICIs) regardless of the anatomic location. Here, we describe clinical outcomes and surgical conversion of MSI-H BTC treated with ICIs. Patients and Methods We conducted a multicenter, retrospective analysis of BTC patients with dMMR/MSI-H between 2017 and 2024 at Mayo Clinic, University of Michigan, and University Hospitals Seidman Cancer Center. Outcomes of interest were surgical resection rate, rate of pathologic response, 2-year overall survival (OS; time from initiation of treatment to death/last follow-up), and time to treatment discontinuation (TTD; time from initiation of treatment to cessation because of any cause). Analyses were descriptive. RESULTS Thirty patients with MSI-H BTC were identified: 19 with cholangiocarcinoma, three with gallbladder cancer, and 8 with BTC undefined. The median age at diagnosis was 61.5 years (range, 26-86). Twenty-six (86.7%) patients had advanced stage at diagnosis. Twenty-seven patients (90%) received first-line systemic therapy, and 13 (48.1%) continued onto second line. Six patients (23.1%) were restaged to resectable from advanced disease after ICI therapy and underwent resection; all remained recurrence-free at last follow-up. Of these six patients, 3 (50%) achieved a pathologic complete response. Among those receiving first-line therapy, the median TTD was 9.9 months (95% CI, 5.7 to 14.5 months) and the 2-year OS was 73% (95% CI, 56% to 94%). CONCLUSION ICI therapy in patients with MSI-H BTC demonstrated durable response and downstaged some BTC to a resectable stage. dMMR/MSI-H should be performed up-front to guide treatment decisions.
AI-Enabled Acute Kidney Injury Prediction and the Challenge of Prevention
Thongprayoon, Charat, Pesce, Francesco, Thongprayoon, Charat , Pesce, Francesco , Cheungpasitporn, Wisit

JAMA Network Open | July 10, 2026 | Volume: 9 | Issue: 7 | Pages: e2622565

10.1001/jamanetworkopen.2026.22565 | PMID 42430174 Get It

Auto Transfusion-Can It Be Used as an Alternative to Pre-Hospital Fresh Blood in Severe Shock Where Blood Is Not Available?
Gavriely, Noam, Hirschhorn, Gil, Marfori, Joseph, Gavriely, Efrat, Murdock, Larry R., Rasanen, Jukka O., Marfori, Joseph, Räsänen, Jukka

Hemato | July 10, 2026 | Volume: 7 | Issue: 3 | Pages: 23

10.3390/hemato7030023 Get It

Pre-hospital use of whole blood is becoming increasingly prevalent in EMS and military medicine. Technologies to store, transport, warm up, and transfuse the blood are now available, and the outcome of whole blood transfusion seems to be superior to infusion of crystalloid solutions or plasma and at least equivalent to packed cells with plasma. The auto-transfusion tourniquet (A-TT®, Oneg HaKarmel Ltd., Tirat Carmel, Israel) is a non-invasive device that shifts the patient’s own blood from the legs to the core and blocks its reentry. The A-TT consists of an elastic ring made of a stainless-steel coil, wrapped by an elastic sleeve and pulling straps. When rolled up the leg(s), it squeezes the soft-tissues’ blood into the central circulation, and the ring stops the return of blood to the leg. The application time of the A-TT is less than 20 s per leg, and the A-TT transfers more than 500 mL of blood from each leg to the core. The auto-transfused blood is of the patient’s own type, has full oxygen carrying capacity, is normothermic, and is not anticoagulated. The device can be applied by a trained first responder, even during transport, and its use can be titrated to avoid overshooting the patient’s blood pressure. The device can be kept on the leg for up to 2 h, and as such, can serve as a bridge to blood or a bridge to definitive care. This paper is a hypothesis-generating review that defines the potential role of the A-TT in settings where blood is not available and is a call for others to help generate more data.